Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins

Biochimica et Biophysica Acta - Biomembranes

Volumn 1768, Issue 8, 2007, Pages 1923-1934

  Murphy, Regina M ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

Amyloid; Beta amyloid; Fibril; Kinetic; Lipid bilayer

Indexed keywords

AMYLOID PROTEIN; BETA SECRETASE; INSULIN; OLIGOMER; PREALBUMIN; PRION PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; HUMAN; KINETICS; LIPID BILAYER; MOLECULAR INTERACTION; MOLECULAR MODEL; MORPHOLOGY; PARKINSON DISEASE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; HUMANS; KINETICS; LIPID BILAYERS; MODELS, BIOLOGICAL; PARKINSON DISEASE; PEPTIDES;

EID: 34547156274     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.12.014     Document Type: Review

References (91)

1. Hart P.J. Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr. Opin. Chem. Biol. 10 (2006) 131-138
2. Chi E.Y., Krishnan S., Randolph T.W., and Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20 (2003) 1325-1336
3. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J.S., Taddei N., Ramponi G., Dobson C.M., and Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
4. Ward R.V., Jennings K.H., Jepras R., Neville W., Owen D.E., Hawkins J., Christie G., Davis J.B., George A., Karran E.H., and Howlett D.R. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348 (2000) 137-144
5. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
6. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
7. Ross C.A., and Poirier M.A. What is the role of protein aggregation in neurodegeneration?. Nat. Rev., Mol. Cell Biol. 6 (2005) 891-898
8. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
9. Kirkitadze M.D., Bitan G., and Teplow D.B. Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 69 (2002) 567-577
10. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., and Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy - Evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159 (2001) 1993-2000
11. Hartley D.M., Walsh D.M., Ye C.P.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
12. Liu D.X., Xu Y.C., Feng Y., Liu H., Shen X., Chen K.X., Ma J.P., and Jiang H.L. Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide. Biochemistry 45 (2006) 10963-10972
13. Walsh D.M., Townsend M., Podlisny M.B., Shankar G.M., Fadeeva J.V., El Agnaf O., Hartley D.M., and Selkoe D.J. Certain inhibitors of synthetic amyloid beta-peptide (A beta) fibrillogenesis block oligomerization of natural A beta and thereby rescue long-term potentiation. J. Neurosci. 25 (2005) 2455-2462
14. Zhang X.Q., Smith D.L., Merlin A.B., Engemann S., Russel D.E., Roark M., Washington S.L., Maxwell M.M., Marsh J.L., Thompson L.M., Wanker E.E., Young A.B., Housman D.E., Bates G.P., Sherman M.Y., and Kazantsev A.G. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 892-897
15. Kim J.R., and Murphy R.M. Mechanism of accelerated assembly of beta-amyloid filaments into fibrils by KLVFFK6. Biophys. J. 86 (2004) 3194-3203
16. Gibson T.J., and Murphy R.M. Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context. Biochem. 44 (2005) 8898-8907
17. Bodner R.A., Outeiro T.F., Altmann S., Maxwell M.M., Cho S.H., Hyman B.T., McLean P.J., Young A.B., Housman D.E., and Kazantsev A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4246-4251
18. Hou L.M., Shao H.Y., Zhang Y.B., Li H., Menon N.K., Neuhaus E.B., Brewer J.M., Byeon I.J.L., Ray D.G., Vitek M.P., Iwashita T., Makula R.A., Przybyla A.B., and Zagorski M.G. Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. Soc. 126 (2004) 1992-2005
19. Maiti N.C., Apetri M.M., Zagorski M.G., Carey P.R., and Anderson V.E. Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein. J. Am. Chem. Soc. 126 (2004) 2399-2408
20. Wang X.L., Vitalis A., Wyczalkowski M.A., and Pappu R.V. Characterizing the conformational ensemble of monomeric polyglutamine. Prot. Struct. Funct. Bioinformat. 63 (2006) 297-311
21. Vilasi S., Dosi R., Iannuzzi C., Malmo C., Parente A., Irace G., and Sirangelo I. Kinetics of amyloid aggregation of mammal apomyoglobins and correlation with their amino acid sequences. FEBS Lett. 580 (2006) 1681-1684
22. Baskakov I.V., Legname G., Prusiner S.B., and Cohen F.E. Folding of prion protein to its native alpha-helical conformation is under kinetic control. J. Biol. Chem. 276 (2001) 19687-19690
23. McLaughlin R.W., De Stigter J.K., Sikkink L.A., Baden E.M., and Ramirez-Alvarado M. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein Sci. 15 (2006) 1710-1722
24. Lai Z.H., Colon W., and Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35 (1996) 6470-6482
25. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., Uversky V.N., and Fink A.L. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40 (2001) 6036-6046
26. Quintas A., Vaz D.C., Cardoso I., Saraiva M.J.M., and Brito R.M.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276 (2001) 27207-27213
27. Yong W., Lomakin A., Kirkitadze M.D., Teplow D.B., Chen S.H., and Benedek G.B. Structure determination of micelle-like intermediates in amyloid beta-protein fibril assembly by using small angle neutron scattering. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 150-154
28. Huang T.H.J., Yang D.S., Plaskos N.P., Go S., Yip C.M., Fraser P.E., and Chakrabartty A. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297 (2000) 73-87
29. Tanaka M., Machida Y., Nishikawa Y., Akagi T., Hashikawa T., Fujisawa T., and Nukina N. Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. J. Biol. Chem. 278 (2003) 34717-34724
30. Mukai H., Isagawa T., Goyama E., Tanaka S., Bence N.F., Tamura A., Ono Y., and Kopito R.R. Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10887-10892
31. Wacker J.L., Zareie M.H., Fong H., Sarikaya M., and Muchowski P.J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat. Struct. Mol. Biol. 11 (2004) 1215-1222
32. Baskakov I.V., Legname G., Baldwin M.A., Prusiner S.B., and Cohen F.E. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277 (2002) 21140-21148
33. Harper J.D., Wong S.S., Lieber C.M., and Lansbury P.T. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38 (1999) 8972-8980
34. Serpell L.C., Blake C.C.F., and Fraser P.E. Molecular structure of a fibrillar Alzheimer's Abeta fragment. Biochemistry 39 (2000) 13269-13275
35. Lashuel H.A., Wurth C., Woo L., and Kelly J.W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochem. 38 (1999) 13560-13573
36. Makin O.S., and Serpell L.C. Structures for amyloid fibrils. FEBS J. 272 (2005) 5950-5961
37. Jansen R., Dzwolak W., and Winter R. Amyloidogenic self-assembly of insulin aggregates probed by high resolution atomic force microscopy. Biophys. J. 88 (2005) 1344-1353
38. Paravastu A.K., Petkova A.T., and Tycko R. Polymorphic fibril formation by residues 10-40 of the Alzheimer's beta-amyloid peptide. Biophys. J. 90 (2006) 4618-4629
39. Petkova A.T., Leapman R.D., Guo Z.H., Yau W.M., Mattson M.P., and Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307 (2005) 262-265
40. Huang T.H.J., Yang D.S., Fraser P.E., and Chakrabartty A. Alternate aggregation pathways of the Alzheimer beta-amyloid peptide-An in vitro model of preamyloid. J. Biol. Chem. 275 (2000) 36436-36440
41. Nichols M.R., Moss M.A., Reed D.K., Cratic-McDaniei S., Hoh J.H., and Rosenberry T.L. Amyloid-beta protofibrils differ from Amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J. Biol. Chem. 280 (2005) 2471-2480
42. Williams A.D., Sega M., Chen M.L., Kheterpal I., Geva M., Berthelier V., Kaleta D.T., Cook K.D., and Wetzel R. Structural properties of A beta protofibrils stabilized by a small molecule. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7115-7120
43. Georgalis Y., Starikov E.B., Hollenbach B., Lurz R., Scherzinger E., Saenger W., Lehrach H., and Wanker E.E. Huntingtin aggregation monitored by dynamic light scattering. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6118-6121
44. Poirier M.A., Li H.L., Macosko J., Cai S.W., Amzel M., and Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277 (2002) 41032-41037
45. Tycko R. Molecular structure of amyloid fibrils: insights from solid-state NMR. Q. Rev. Biophys. 39 (2006) 1-55
46. Myers S.L., Thomson N.H., Radford S.E., and Ashcroft A.E. Investigating the structural properties of amyloid-like fibrils formed in vitro from beta 2-microglobulin using limited proteolysis and electrospray ionisation mass spectrometry. Rapid Commun. Mass Spec. 20 (2006) 1628-1636
47. Inouye H., Bond J.E., Deverin S.P., Lim A., Costello C.E., and Kirschner D.A. Molecular organization of amyloid protofilament-like assembly of betabellin 15D: Helical array of beta-sandwiches. Biophys. J. 83 (2002) 1716-1727
48. Sharma D., Shinchuk L.M., Inouye H., Wetzel R., and Kirschner D.A. Polyglutamine homopolymers having 8-45 residues form slablike beta-crystallite assemblies. Prot. Struct. Funct. Bioinformat. 61 (2005) 398-411
49. Williams A.D., Shivaprasad S., and Wetzel R. Alanine scanning mutagenesis of A beta(1-40) amyloid fibril stability. J. Mol. Biol. 357 (2006) 1283-1294
50. Jimenez J.L., Nettleton E.J., Bouchard M., Robinson C.V., Dobson C.M., and Saibil H.R. The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9196-9201
51. De Jong K.L., Incledon B., Yip C.M., and DeFelippis M.R. Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy. Biophys. J. 91 (2006) 1905-1914
52. Pallitto M.M., and Murphy R.M. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys. J. 81 (2001) 1805-1822
53. Hasegawa K., Ono K., Yamada M., and Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry 41 (2002) 13489-13498
54. Cannon M.J., Williams A.D., Wetzel R., and Myszka D.G. Kinetic analysis of beta-amyloid fibril elongation. Anal. Biochem. 328 (2004) 67-75
55. Kelly J.W. Mechanisms of amyloidogenesis. Nat. Struct. Biol. 7 (2000) 824-826
56. Fezoui Y., and Teplow D.B. Kinetic studies of amyloid beta-protein fibril assembly-Differential effects of alpha-helix stabilization. J. Biol. Chem. 277 (2002) 36948-36954
57. Roher A.E., Chaney M.O., Kuo Y.M., Webster S.D., Stine W.B., Haverkamp L.J., Woods A.S., Cotter R.J., Tuohy J.M., Krafft G.A., Bonnell B.S., and Emmerling M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271 (1996) 20631-20635
58. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., and Klein W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42 (2003) 12749-12760
59. Vendrely C., Valadie H., Bednarova L., Cardin L., Pasdeloup M., Cappadoro K., Bednar J., Rinaudo M., and Jamin M. Assembly of the full-length recombinant mouse prion protein I. Formation of soluble oligomers. Biochim. Biophys. Acta, Gen. Subj. 1724 (2005) 355-366
60. Gibson T.J., and Murphy R.M. Inhibition of insulin fibrillogenesis with targeted peptides. Prot. Sci. 15 (2006) 1133-1141
61. Manno M., Craparo E.F., Martorana V., Bulone D., and San Biagio P.L. Kinetics of insulin aggregation: disentanglement of amyloid fibrillation from large-size cluster formation. Biophys. J. 90 (2006) 4585-4591
62. Ahmad A., Uversky V.N., Hong D., and Fink A.L. Early events in the fibrillation of monomeric insulin. J. Biol. Chem. 280 (2005) 42669-42675
63. F. Ferrone, Analysis of protein aggregation kinetics. Amyloid, Prions, and Other Protein Aggregates (1999) 256-274.
64. Chen S.M., Ferrone F.A., and Wetzel R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11884-11889
65. Powers E.T., and Powers D.L. The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration". Biophys. J. 91 (2006) 122-132
66. Naiki H., and Nakakuki K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest. 74 (1996) 374-383
67. Esler W.P., Stimson E.R., Jennings J.M., Vinters H.V., Ghilardi J.R., Lee J.P., Mantyh P.W., and Maggio J.E. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39 (2000) 6288-6295
68. Massi F., and Straub J.E. Energy landscape theory for Alzheimer's amyloid beta-peptide fibril elongation. Prot. Struct. Funct. Genet. 42 (2001) 217-229
69. Roberts C.J. Nonnative protein aggregation: pathways, kinetics, and stability prediction. In: Murphy R.M., and Tsai A.M. (Eds). Misbehaving Proteins: Protein (Mis)folding, Aggregation, and Stability (2006), Springer, New York 353
70. Hall D., Hirota N., and Dobson C.M. A toy model for predicting the rate of amyloid formation from unfolded protein. J. Mol. Biol. 351 (2005) 195-205
71. Hall C.K., Nguyen H.D., Marchut A.J., and Wagoner V. Simulations of Protein Aggregation. In: Murphy R.M., and Tsai A.M. (Eds). Misbehaving Proteins: Protein (Mis)folding, Aggregation, and Stability (2006), Springer, New York 353
72. Harrison P.M., Chan H.S., Prusiner S.B., and Cohen F.E. Conformational propagation with prion-like characteristics in a simple model of protein folding. Protein Sci. 10 (2001) 819-835
73. Pellarin R., and Caflisch A. Interpreting the aggregation kinetics of amyloid peptides. J. Mol. Biol. 360 (2006) 882-892
74. Marchut A.J., and Hall C.K. Spontaneous formation of annular structures observed in molecular dynamics simulations of polyglutamine peptides. Comput. Biol. Chem. 30 (2006) 215-218
75. Marchut A.J., and Hall C.K. Side-chain interactions determine amyloid formation by model polyglutamine peptides in molecular dynamics simulations. Biophys. J. 90 (2006) 4574-4584
76. Nguyen H.D., and Hall C.K. Kinetics of fibril formation by polyalanine peptides. J. Biol. Chem. 280 (2005) 9074-9082
77. Nguyen H.D., and Hall C.K. Spontaneous fibril formation by polyalanines: discontinuous molecular dynamics simulations. J. Am. Chem. Soc. 128 (2006) 1890-1901
78. Good T.A., and Murphy R.M. Aggregation state-dependent binding of beta-amyloid peptide to protein and lipid components of rat cortical homogenates. Biochem. Biophys. Res. Commun. 207 (1995) 209-215
79. Kremer J.J., and Murphy R.M. Kinetics of adsorption of beta-amyloid peptide A beta(1-40) to lipid bilayers. J. Biochem. Biophys. Methods 57 (2003) 159-169
80. Kremer J.J., Pallitto M.M., Sklansky D.J., and Murphy R.M. Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 39 (2000) 10309-10318
81. Kurganov B., Doh M., and Arispe N. Aggregation of liposomes induced by the toxic peptides Alzheimer's Abeta, human amylin and prion (106-126): facilitation by membrane-bound G(M1) ganglioside. Peptides 25 (2004) 217-232
82. Suopanki J., Gotz C., Lutsch G., Schiller J., Harjes P., Herrmann A., and Wanker E.E. Interaction of huntingtin fragments with brain membranes-Clues to early dysfunction in Huntington's disease. J. Neurochem. 96 (2006) 870-884
83. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., and Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
84. Engel M.F.M., Yigittop H., Elgersma R.C., Rijkers D.T.S., Liskamp R.M.J., de Kruijff B., Hoppener J.W.M., and Killian J.A. Islet amyloid polypelptide inserts into phospholipid monolayers as monomer. J. Mol. Biol. 356 (2006) 783-789
85. Ji S.R., Wu Y., and Sui S.F. Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (Abeta 1-40), which may potentially inhibit the fibril formation. J. Biol. Chem. 277 (2002) 6273-6279
86. Yip C.M., and McLaurin J. Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys. J. 80 (2001) 1359-1371
87. Cox D.L., Sing R.R.P., and Yang S.C. Prion disease: exponential growth requires membrane binding. Biophys. J. 90 (2006) 77-79
88. Sharp J.S., Forrest J.A., and Jones R.A.L. Surface denaturation and amyloid fibril formation of insulin at model lipid-water interfaces. Biochemistry 41 (2002) 15810-15819
89. Sabate R., Gallardo M., and Estelrich J. Spontaneous incorporation of beta-amyloid peptide into neutral liposomes. Colloids Surf., A Physicochem. Eng. Asp. 270 (2005) 13-17
90. Sabate R., and Estelrich J. Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. Langmuir 21 (2005) 6944-6949
91. Bokvist M., Lindstrom F., Watts A., and Grobner G. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring Versus accelerated surface fibril formation. J. Mol. Biol. 335 (2004) 1039-1049